SEC Form 4 · accession 0001179110-15-012913
MEDICINES CO /DE · MDCO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clive Meanwell
Officer — CEO · Director
Period of report
Aug 31, 2015
Accepted (ET)
Sep 2, 2015 · 6:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113481
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 31, 2015 | A | 429 | $24.74 | A | 324,905 | D | |
| Common Stock | Aug 31, 2015 | M | 49,998 | $18.27 | A | 374,903 | D | |
| Common StockF2,F3 | Aug 31, 2015 | S | 49,998 | $39.359 | D | 324,905 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right-to-buy)F5,F4 | $18.27 | Aug 31, 2015 | M | 49,998 | D | — | Nov 30, 2015 | Common Stock | 49,998 | 0 | D |
Explanation of responses
- F1Acquired pursuant to The Medicines Company Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period beginning March 1, 2015 and ending August 31, 2015. In accordance with the terms of the ESPP, these shares were purchased based on 85% of the fair market value closing price of the issuer's common stock on March 2, 2015.
- F2Sales were effected pursuant to a Rule 10b5-1 program adopted by Dr. Meanwell.
- F3Represents the weighted average sales price of the shares sold ranging from a low of $37.60 to a high of $40.57 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4This option vested in forty-eight equal installments beginning on December 30, 2005.
- F5Not applicable.